2. Academic Validation
  3. GITR Antibodies in Cancer: Not Ready for Prime Time

GITR Antibodies in Cancer: Not Ready for Prime Time

  • Clin Cancer Res. 2022 Sep 15;28(18):3905-3907. doi: 10.1158/1078-0432.CCR-22-1489.
Tatiana Hernandez-Guerrero 1,  Victor Moreno 1
Affiliations

Affiliation

  • 1 START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.
PMID: 35834593 DOI: 10.1158/1078-0432.CCR-22-1489
Abstract

Glucocorticoid-induced TNF Receptor (TNFR)-related protein (GITR) agonistic Antibodies are expected to increase the antitumor response mainly by reducing the effect of Foxp3+ T-regulatory cells. TRX-518 is a novel GITR Agonist that has shown good pharmacodynamic activity by depleting regulatory T cells (Tregs) in preclinical models, with limited clinical activity demonstrated in patients with advanced solid tumors. See related article by Davar et al., p. 3990.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z